¹⁸F-FDG-PET/CT for Detection of Extramedullary Acute Myeloid Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2011 Jun 21

PMID 21685468

Citations 47

Authors

Friedrich Stolzel

Christoph Rollig

Jorgen Radke

Brigitte Mohr

Uwe Platzbecker

Martin Bornhauser

Tobias Paulus

Gerhard Ehninger

Klaus Zophel

Markus Schaich

Affiliations

Soon will be listed here.

Abstract

Myeloid sarcoma in acute myeloid leukemia has been clearly defined by the World Health Organization but studies regarding the prevalence and the prognostic impact of extramedullary acute myeloid leukemia have not been conducted. We performed (18)Fluoro-deoxy-Glucose Positron Emission Tomography/Computed Tomography scans in 10 patients with de novo and relapsed acute myeloid leukemia and histologically proven extramedullary disease. The scans were able to detect the known extramedullary lesions in 9 out of 10 patients (90%). Furthermore, additional extramedullary sites were detected in 6 patients (60%). Thus, it is possible to identify known and clinically undetectable extramedullary manifestations of acute myeloid leukemia. Since most of these patients relapsed within a short period of time after initiation of therapy or had refractory disease, the detection of extramedullary disease with (18)Fluoro-deoxy-Glucose Positron Emission Tomography/Computed Tomography might be helpful in the development of individual treatment algorithms for these high-risk patients.

Citing Articles

Diagnostic Approaches in Myeloid Sarcoma.

Patkowska E, Krzywdzinska A, Solarska I, Wojtas M, Prochorec-Sobieszek M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996833 PMC: 11853749. DOI: 10.3390/cimb47020111.

Myeloid sarcoma: more and less than a distinct entity.

Loscocco G, Vannucchi A Ann Hematol. 2023; 102(8):1973-1984.

PMID: 37286874 PMC: 10345021. DOI: 10.1007/s00277-023-05288-1.

Extramedullary Myeloid Leukemia in the Setting of a Myeloproliferative Neoplasm.

Kosti J, Mervak T, Terebelo H J Med Cases. 2022; 13(11):561-568.

PMID: 36506761 PMC: 9728152. DOI: 10.14740/jmc3996.

Myeloid sarcoma with ulnar nerve entrapment: A case report.

Li D, Liu C, Jeremy M, Li X, Wang J, Nath Varma S World J Clin Cases. 2022; 10(28):10227-10235.

PMID: 36246824 PMC: 9561602. DOI: 10.12998/wjcc.v10.i28.10227.

Vulvovaginal myeloid sarcoma with massive pelvic floor infiltration: A case report and review of literature.

Wang J, Zhang H, Ning G, Bao L World J Clin Cases. 2022; 10(23):8312-8322.

PMID: 36159511 PMC: 9403691. DOI: 10.12998/wjcc.v10.i23.8312.

References

Falini B, Lenze D, Hasserjian R, Coupland S, Jaehne D, Soupir C . Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia. 2007; 21(7):1566-70. DOI: 10.1038/sj.leu.2404699. View

Kuenzle K, Taverna C, Steinert H . Detection of extramedullary infiltrates in acute myelogenous leukemia with whole-body positron emission tomography and 2-deoxy-2-[18F]-fluoro-D-glucose. Mol Imaging Biol. 2003; 4(2):179-83. DOI: 10.1016/s1095-0397(01)00056-5. View

Pileri S, Ascani S, Cox M, Campidelli C, Bacci F, Piccioli M . Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2006; 21(2):340-50. DOI: 10.1038/sj.leu.2404491. View

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

Dohner K, Schlenk R, Habdank M, Scholl C, Rucker F, Corbacioglu A . Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005; 106(12):3740-6. DOI: 10.1182/blood-2005-05-2164. View

Buck A, Bommer M, Juweid M, Glatting G, Stilgenbauer S, Mottaghy F . First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine. J Nucl Med. 2008; 49(11):1756-62. DOI: 10.2967/jnumed.108.055335. View

Schaich M, Schlenk R, Al-Ali H, Dohner H, Ganser A, Heil G . Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica. 2007; 92(6):763-70. DOI: 10.3324/haematol.11100. View

Tsimberidou A, Kantarjian H, Wen S, Keating M, OBrien S, Brandt M . Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008; 113(6):1370-8. PMC: 2574728. DOI: 10.1002/cncr.23691. View

Mortimer J, Blinder M, Schulman S, Appelbaum F, Buckner C, Clift R . Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol. 1989; 7(1):50-7. DOI: 10.1200/JCO.1989.7.1.50. View

10.

Aschoff P, Hantschel M, Oksuz M, Werner M, Lichy M, Vogel W . Integrated FDG-PET/CT for detection, therapy monitoring and follow-up of granulocytic sarcoma. Initial results. Nuklearmedizin. 2009; 48(5):185-91. DOI: 10.3413/nukmed-0236. View

11.

Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D . Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006; 108(3):1092-9. DOI: 10.1182/blood-2005-10-4165. View

12.

Boellaard R, ODoherty M, Weber W, Mottaghy F, Lonsdale M, Stroobants S . FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2009; 37(1):181-200. PMC: 2791475. DOI: 10.1007/s00259-009-1297-4. View

13.

von Falck C, Laenger F, Knapp W, Galanski M . F-18 FDG PET/CT showing bilateral breast involvement in acute myeloid leukemia relapse. Clin Nucl Med. 2009; 34(10):713-5. DOI: 10.1097/RLU.0b013e3181b53a6d. View

14.

Chong G, Byrnes G, Szer J, Grigg A . Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant. 2000; 26(9):1011-5. DOI: 10.1038/sj.bmt.1702659. View

15.

Hutchings M, Specht L . PET/CT in the management of haematological malignancies. Eur J Haematol. 2008; 80(5):369-80. DOI: 10.1111/j.1600-0609.2008.01051.x. View

16.

Cunningham I . Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma. 2006; 47(9):1754-67. DOI: 10.1080/10428190600632857. View

17.

Ueda K, Ichikawa M, Takahashi M, Momose T, Ohtomo K, Kurokawa M . FDG-PET is effective in the detection of granulocytic sarcoma in patients with myeloid malignancy. Leuk Res. 2010; 34(9):1239-41. DOI: 10.1016/j.leukres.2010.04.017. View

18.

Juweid M . FDG-PET/CT in lymphoma. Methods Mol Biol. 2011; 727:1-19. DOI: 10.1007/978-1-61779-062-1_1. View

19.

Mantzarides M, Bonardel G, Fagot T, Gontier E, Soret M, Revel T . Granulocytic sarcomas evaluated with F-18-fluorodeoxyglucose PET. Clin Nucl Med. 2008; 33(2):115-7. DOI: 10.1097/RLU.0b013e31815ef799. View

20.

Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M . Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006; 107(10):4011-20. DOI: 10.1182/blood-2005-08-3167. View